This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
San Diego-based Avelas Biosciences has raised $7.65M in a Series A funding round, which it says will go towards clinical studies for its technology for real-time tumor visualization. The funding came from Avalon Ventures. Avelas is developingtechnology for visualizing cancerous lymph nodes in breast cancer patients.
San Diego-based Chumby , which had developed Internet-connected, alarm-clock like devices and similar technology, has shut down, according to a report Friday. The Verge, which first reported the news, said that Chumby's employees are now working for Technicolor, and the firm is looking to sell off its technology. READ MORE>>.
San Diego-based Avelas Biosciences announced today that it has raised $6.85M in a Series B funding round, for the company''s technology for illuminating cancer cells. The company said the funding came from Avalon Ventures, and also included Torrey Pines Investment, WuXi AppTec, and an additional, un-named investor. READ MORE>>.
San Diego-based Avelas Biosciences , which is developing cell penetrating peptides to light up cancerous tissue in patients during surgery, has raised $7.4M The second tranche of the company''s Series B came from investors Avalon Ventures, Torrey Pines Investment and WuXi PharmaTech Investments. in a Series B funding.
San Diego-based server side caching software developer Proximal Data has inked a deal with LSI Corporation , where LSI will integrate its server-side caching technology with a PCIe flash application acceleration product. Proximal Data is venture backed by Divergent Ventures and Avalon Ventures. READ MORE>>.
Chumby has previously raised funding from Avalon Ventures, JK&B Capital, Masthead Venture Partners, and O'Reilly AlphaTech Ventures. Chumby's Internet device allows users to run information widgets, and includes tools for developers which makes it easy to create those software widgets to connect to Internet services.
San Diego-based Proximal Data , a developer of storage caching software aimed at use with virtualized systems, has been acquired by Samsung Electronics , Samsung said today. Proximal Data was venture backed by Divergent Ventures and Avalon Ventures, and had only announced around $5M in funding.
San Diego-based COI Pharmaceuticals , the life sciences incubator and support entity created by Avalon Ventures to support its portfolio companies, says that one of its companies, Calporta Therapeutics , has been acquired by Merck. The deal is worth up to $576M, including upfront payments and contingent milestone payments. READ MORE>>.
San Diego-based Proximal Data , which develops serve-side caching software for accelerating I/O access to virtualized machines, said this morning that it has raised $2M in a Series B round of funding. The funding came from Divergent Ventures, along with existing investors Avalon Ventures. The firm is led by Rory Bolt. READ MORE>>.
La Jolla-based Ortiva Wireless , which developstechnology to stream video to mobile devices, reports today that it has hired on a new, Senior Vice President of Worldwide Sales, James D. Ortiva is backed by Comcast, Artiman Ventures, Mission Ventures, and Avalon Ventures. READ MORE>>.
San Diego-based Synthorx , a developer of protein therapeutics technology, said it has raised $10M in a Series B financing this morning. The funding was led by RA Capital Management, and also included Avalon Ventures and Correlation Ventures. The company's technology is based on research from The Scripps Research Institute.
in a Series A financing for the firm's biopharmaceuticals technology. According to the firm, the financing came from Avalon Ventures LLC. Zacharon Pharmaceutical is developing glycan inhibitors which have appications in treating genetic disorders and oncology. The firm also said it has received more than $2.2M
San Diego-based E-Band Communications , a developer of millimeter-wave wireless transmission systems, said Wednesday that the firm has raised a Series C financing round. According to E-Band, the round was led by Hercules Technology Growth Capital, and also included Avalon Ventures.
The funding was led by Avalon Ventures and TPG Biotech, and also included Correlation Ventures and Osage University Partners. The startup said it is developing novel drugs based on the anti-cancer activity of metformin and designed to reduce cancer energy production to treat a range of cancer types. READ MORE>>.
San Diego-based Ambit Biosciences , a developer of small molecule profiling tools being used for biopharmaceuticals development, has raised $6.5M in an ongoing, debt round, according to a filing from the firm today. in debt, including warrants in the firm. in debt, including warrants in the firm.
San Diego-based Awarepoint, a developer of systems for tracking assets and patients in hospitals, has raised $13.3M The firm said the round was led by Cardinal partners, and also included Venrock and prior investor Avalon Ventures. in a Series D funding. The firm offers its services as software-as-a-service to the healthcare industry.
La Jolla-based Ortiva Wireless , a developer of products for managing mobile video streaming, said this morning that it has signed on Mobix Interactive as a customer. Ortiva's venture backers are Artiman Ventures, Avalon Ventures, Comcast, and Mission Ventures. Financial impact of the customer win was not disclosed. READ MORE>>.
San Diego-based AristaMD , which is developing software tools to help coordinate referrals by physicians to specialists, has raised $11M in a Series A funding round. The funding was led by Avalon Ventures, and also included Correlation Ventures. READ MORE>>.
Irvine-based Broadcom and San Diego-based Chumby are working together to integrate Chumby's technology into set top boxes, the firms announced this morning. According to the companies, the integration of that technology onto Broadcom's digital TV chips will allow users to personalize their user experience on Internet-connected TVs.
Fortis Therapeutics, a new San Diego biotech, has raised $18 million in initial funding to develop drugs for hard-to-treat prostate and bone marrow cancers. San Diego’s Avalon Ventures led the Series A round, and has established Fortis at COI Pharma, the firm’s biotech incubator (which now houses 16 life sciences startups).
Roger Tsien, a UC San Diego scientist who shared the 2008 Nobel Prize in chemistry for research that led to the development of fluorescent proteins used to illuminate tissue and track biological processes, has died, according to a statement from the university. He compared himself to John C. Reprints | Share: UNDERWRITERS AND PARTNERS.
and San Diego’s Avalon Ventures. Avelas plans to use the new funding to advance development of AVB-620, the company’s lead diagnostic agent, for use in breast cancer surgeries, CEO Carmine Stengone told me yesterday. Avalon partner Jay Lichter plans to continue serving as Avelas’ chairman, Stengone said.
Synthorx, which is working to develop cancer and autoimmune therapies using technology that allows it to expand the genetic alphabet, raised $131 million in an upsized IPO on Thursday. The company sold more than 11.9 million shares at $11 apiece. million additional shares are available for its underwriters to purchase.
Existing investors Avalon Ventures and Correlation Ventures joined in the round. An unnamed pharmaceutical company also is providing additional undisclosed funding under a drug development deal signed in February, Turner said. coli bacteria and to make proteins that incorporate synthetic amino acids.
Who will break free of the pack of companies developing drugs meant to prevent migraines? —Amgen (NASDAQ: AMGN ), of Thousand Oaks, CA, and partner Novartis released positive results from the first Phase 3 trial of erenumab , one of a group of drugs being developed to prevent migraines , not just lessen their impact when they happen.
The Connected Car , where automotive and technology (outside of vehicle performance and earth saving “greenness”) collide. Auto-interfaces are clunky, and when a lot of these big tech companies IPO’d, a lot of them developed products that were endemic to the car industry – navigation, social graphs, etc.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content